1). Inatomi T, Spurr-Michaud S, Tisdale AS, et al. Expression of secretory mucin genes by human conjunctival epithelia. Invest Ophthalmol Vis Sci. 1996; 37:1684–92.
2). Fahmy AM, Hardten DR. Treating ocular surface disease: new agents in development. Clin Ophthalmol. 2011; 5:465–72.
3). Jung HH, Kang YS, Sung MS, Yoon KC. Clinical efficacy of topical 3% diquafosol tetrasodium in short tear film break-up time dry eye. J Korean Ophthalmol Soc. 2015; 56:339–44.
Article
4). Fujihara T, Murakami T, Nagano T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002; 18:363–70.
Article
5). Fujihara T, Murakami T, Fujita H, et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001; 42:96–100.
6). Miyake G, Ota I, Miyake K, et al. Effects of topical diquafosol pretreatment on intraoperative corneal wetting. J Cataract Refract Surg. 2014; 40:1682–8.
Article
7). Marko CK, Menon BB, Chen G, et al. Spdef null mice lack conjunctival goblet cells and provide a model of dry eye. Am J Pathol. 2013; 183:35–48.
Article
8). Woo JM, Jeung WJ, Park WC. Conjunctival epithelial cells auto-cultivated in vivo on human amniotic membrane in rabbits. J Korean Ophthalmol Soc. 2006; 47:812–7.
9). Helleboid L, Khatami M, Wei ZG, Rockey JH. Histamine and prostacyclin. Primary and secondary release in allergic conjunctivitis. Invest Ophthalmol Vis Sci. 1991; 32:2281–9.
10). Rothman JS, Raizman MB, Friedlaender MH. Seasonal and perennial allergic conjunctivitis. Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea. 3rd ed.St Louis: Mosby Elsevier Inc.;2010. p. 567–8.
Article
11). Terakado K, Yogo T, Kohara Y, et al. Conjunctival expression of the P2Y2 receptor and the effects of 3% diquafosol ophthalmic solution in dogs. Vet J. 2014; 202:48–52.
Article